| [1] |
Mohamed, R.A.E.; Moustafa, N.M.; Mahmoud, F.M.; Elsaadawy, Y.S.; Abdel Aziz, H.S.; Abou Bakr Gaber, S.; Hussin, A.M.; Seadawy, M.G. Whole-genome sequencing of two multidrug-resistant acinetobacter baumannii strains isolated from a neonatal intensive care unit in Egypt: a prospective cross-sectional study. BMC Microbiol. 2024, 24, 362.
|
| [2] |
Korczak, L.; Majewski, P.; Rombel, K.; Iwaniuk, D.; Sacha, P.; Modzelewski, M.; Tryniszewska, E. In vitro evaluation of tigecycline synergy testing with nine antimicrobial agents against Enterobacter cloacae clinical strains. Front. Microbiol. 2024, 15, 1490032.
|
| [3] |
Fan, X.Y.; Jiang, Y.; Wu, H.; Liu, J.; Gu, Q.Y.; Wang, Z.Y.; Sun, L.; Jiao, X.N.; Li, Q.C.; Wang, J. Distribution and spread of tigecycline resistance gene Tet (X4) in Escherichia coli from different sources. Front. Cell Infect. Microbiol. 2024, 14, 1399732.
|
| [4] |
Cui, N.N.; Cai, H.L.; Li, Z.T.; Lu, Y.T.; Wang, G.B.; Lu, A.W. Tigecycline-induced coagulopathy: a literature review. Int. J. Clin. Pharm. 2019, 41, 1408–1413.
|
| [5] |
Li, Z.K.; Zheng, P. Acute pancreatitis caused by tigecycline and furosemide combination treatment and hypofibrinogenemia caused by tigecycline: a case report. Int. J. Clin. Pharmacol. Ther. 2023, 61, 466–470.
|
| [6] |
Wu, S.Y.; Chen, Y.H.; Fan, W.J.; Wu, X.R.; Zhang, C.F.; Lin, Y.C.; Lin, Q. Predicting tigecycline-related adverse events in infected patients: a machine learning approach with clinical interpretability. Front. Pharmacol. 2025, 16, 1697929.
|
| [7] |
Leng, B.; Xue, Y.C.; Zhang, W.; Gao, T.T.; Yan, G.Q.; Tang, H. A retrospective analysis of the effect of tigecycline on coagulation function. Chem. Pharm. Bull. 2019, 67, 258–264.
|
| [8] |
Guo, M.X.; Liang, J.W.; Li, D.D.; Zhao, Y.; Xu, W.Y.; Wang, L.; Cui, X.L. Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database. Thromb. J. 2022, 20, 12.
|
| [9] |
Li, M.X.; He, J.; Dong, G.Q.; Hu, L.L.; Shao, H. Serum concentration threshold and risk factors of tigecycline-induced hypofibrinogenaemia in critically ill patients. J. Antimicrob. Chemother. 2025, 80, 200–208.
|
| [10] |
Ma, C.Q.; Ren, X.L.; Pang, N.; Liu, Y.K.; Chen, M.F.; Zhang, X.H.; Liu, Y.; Huang, L. Incidence, characteristics, and risk factors of hypofibrinogenemia induced by generic tigecycline: a retrospective study. Naunyn Schmiedeberg’s Arch. Pharmacol. 2025, 398, 2717–2727.
|
| [11] |
Zhang, L.; Cai, X.F.; Peng, F.C.; Tian, S.S.; Wu, X.J.; Li, Y.; Guo, J.L. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies. Front. Pharmacol. 2023, 14, 1182644.
|
| [12] |
Van Dung, H.; Tan, V.M.; Dieu, N.T.; Van Linh, P.; Van Khai, N.; Ngan, T.T.; Phuong, N.T.T. Development and external validation of a machine learning model for predicting drug-induced immune thrombocytopenia in a real-world hospital cohort. BMC Med. Inform. Decis. Mak. 2025, 25, 265.
|
| [13] |
Clerkin, K.J.; Salako, O.; Fried, J.A.; Griffin, J.M.; Raikhelkar, J.; Jain, R.; Restaino, S.; Colombo, P.C.; Takeda, K.; Farr, M.A.; Sayer, G.; Uriel, N.; Topkara, V.K. Impact of temporary percutaneous mechanical circulatory support before transplantation in the 2018 heart allocation system. JACC Heart Fail. 2022, 10, 12–23.
|
| [14] |
Liu, X.Z.; Duan, M.J.; Huang, H.D.; Zhang,Y.; Xiang, T.Y.; Niu, W.C.; Zhou, B.; Wang, H.L.; Zhang, T.T. Predicting diabetic kidney disease for type 2 diabetes mellitus by machine learning in the real world: a multicenter retrospective study. Front. Endocrinol. 2023, 14, 1184190.
|
| [15] |
Sun, T.; Liu, J.; Yuan, H.Q.; Li, X.; Yan, H. Construction of a risk prediction model for lung infection after chemotherapy in lung cancer patients based on the machine learning algorithm. Front. Oncol. 2024, 14, 1403392.
|
| [16] |
Zhu, Y.C.; Zhao, F.; Jin, P.F. Clinical manifestations and risk factors of tigecycline-associated thrombocytopenia. Infect. Drug Resist. 2023, 16, 6225–6235.
|
| [17] |
Wan, Q.Q.; Gao, F.; Ye, Q.F.; Wan, Q.Q.; Liu, S.; Zhou, J.D. Distribution and resistance of pathogens in liver transplant recipients with Acinetobacter baumannii infection. Ther. Clin. Risk Manag. 2015, 501–505.
|
| [18] |
Singh, A.; Uzun, G.; Bakchoul, T. Primary immune thrombocytopenia: novel insights into pathophysiology and disease management. J. Clin. Med. 2021, 10, 789.
|
| [19] |
Du, Y.J.; Yu, L.X.; Deng, B.; Li, Q.Y.; Hu, J.R.; Li, L.J.; Xu, Y.S.; Song, L.W.; Xie, F.; Wang, Y.H.; Chen, Y.H.; Liu, C.X.; Zhai, X.J.; Lu, Y.N. Pharmacokinetic interactions between tegoprazan and the combination of clarithromycin, amoxicillin and bismuth in healthy Chinese subjects: an open-label, single-center, multiple-dosage, self-controlled, phase I trial. Clin. Drug Investig. 2024, 44, 343–355.
|
| [20] |
Vaiyapuri, S.; Ali, M.S.; Moraes, L.A.; Sage, T.Y.; Lewis, K.R.; Jones, C.I.; Gibbins, J.M. Tangeretin regulates platelet function through inhibition of phosphoinositide 3-kinase and cyclic nucleotide signaling. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 2740–2749.
|
| [21] |
Fantin, F.; Manica, A.; Soldani, F.; Bissoli, L.; Zivelonghi, A.; Zamboni, M. Use of tigecycline in elderly patients for Clostridium difficile infection. Geriatr. Gerontol. Int. 2015, 15, 230–231.
|
| [22] |
Han, P.P.; Yu, T.S.; Hou, Y.; Zhao, Y.J.; Liu, Y.; Sun, Y.Q.; Wang, H.Y.; Xu, P.C.; Li, G.S.; Sun, T.; Hu, X.; Liu, X.G.; Li, L.Z.; Peng, J.; Zhou, H.; Hou, M. Low-dose decitabine inhibits cytotoxic T lymphocytes-mediated platelet destruction via modulating PD-1 methylation in immune thrombocytopenia. Front. Immunol. 2021, 12, 630693.
|
| [23] |
Moming, A.; Shi, S.; Shen, S.; Qiao, J.; Yue, X.H.; Wang, B.; Ding, J.T.; Hu, Z.H.; Deng, F.; Zhang, Y.J.; Sun, S.R. Fine mapping epitope on glycoprotein-gn from severe fever with thrombocytopenia syndrome virus. PLoS One. 2021, 16, e0248005.
|
| [24] |
Liu, J.W.; Chu, M.; Jiao, Y.J.; Zhou, C.M.; Qi, R.; Yu, X.J. SFTSV infection induced interleukin-1β secretion through NLRP3 inflammasome activation. Front. Immunol. 2021, 12, 595140.
|
| [25] |
Liu, X.Z.; Liu, J.J.; Xue, W.J.; Xing, H.Y.; Zhao, L.Y.; Fang, X. Retrospective analysis of tigecycline-associated hypofibrinogenemia in patients with hypoproteinemia. J. Chin. Pharm. Sci. 2025, 34, 581–591.
|
| [26] |
Shen, L.; Fang, W.; Zhang, Y.; Pan, Y.; Zhou, Z.W. Retrospective analysis of coagulopathy in patients with severe renal insufficiency caused by tigecycline. China Pharm. 2023, 34, 2766–2769.
|